Substance P has a broad history in neuroscience, but its name refers to a particular peptide rather than a general pain signal. Research may examine its precursor gene, its preferred receptor or the location from which that receptor signals. Separating those objects helps explain what a study contributes without converting a mechanistic result into a symptom-treatment claim.
Define the peptide before following the pathway
The PubChem substance P record specifies RPKPQQFFGLM with a terminal methionine amide. It identifies preferential activation of the neurokinin-1 receptor, commonly abbreviated NK1R.PubChem — Substance P, CID 36511 (opens in a new tab)
The abbreviation SP should be resolved at the first mention because it can be ambiguous outside this literature. Likewise, NK1R identifies a receptor; it is not another way of writing the peptide’s sequence.
| Object | Example measurement |
|---|---|
| Mature peptide | A sequence-specific concentration result |
| Precursor transcript | TAC1 messenger RNA abundance |
| NK1 receptor | Location or activation of the target protein |
| Neuronal response | A measured firing pattern |
These measurements can support a connected explanation, but they cannot substitute for one another. A change in one field should prompt a question about the next step rather than an assumption that every downstream field changed.
TAC1 is broader than substance P alone
NCBI’s reviewed TAC1 record identifies substance P, neurokinin A, neuropeptide K and neuropeptide gamma among the products associated with this precursor gene. It also records multiple transcript variants.NCBI Gene — Human TAC1 (opens in a new tab)
Consequently, a gene-level intervention can have a broader molecular scope than adding or removing one mature peptide. Calling a TAC1 expression result a direct substance P concentration measurement would skip the processing and measurement steps.
For a study using gene disruption, read which mature products the design could affect. For an assay, read whether it recognises the mature peptide, a precursor region or related material.
Internalisation does not always mean signalling has ended
Jensen and colleagues’ 2017 study found that substance P could drive NK1 receptor signalling from endosomes. The work linked receptor internalisation with sustained spinal-neuron excitation and nociceptive responses in experimental systems.Jensen and colleagues — Endosomal NK1 receptor signalling (opens in a new tab)
Its evidence included cellular signalling measurements, rat spinal-cord recordings and mouse nociception experiments. Disrupting internalisation and targeting antagonists to endosomes helped test the contribution of that intracellular signalling location.Jensen and colleagues — Endosomal NK1 receptor signalling (opens in a new tab)
This changes how a receptor image should be read. A receptor disappearing from the cell surface is not, by itself, proof that all signalling has stopped. The next question is what it does in its new compartment.
The study’s animal and cellular findings remain preclinical evidence. A reduction in a mouse withdrawal response does not by itself establish relief of a person’s persistent pain or a safe clinical intervention.
Choose the claim that the observation can support
A useful explanation follows a chain of separate observations: the peptide engages the receptor; the receptor changes location; a defined signal persists; a neuronal or organism-level response is measured. The strength of the account depends on evidence connecting those steps.
If a paper contains only a localisation image, avoid adding a functional conclusion without a corresponding readout. If it contains a functional change, ask whether receptor-specific controls establish which pathway contributed.
For example, the wording more internal receptor is a location claim. Sustained receptor-dependent signalling requires a signal measurement and an appropriate perturbation. A clinical benefit requires a further level of direct evidence.
This keeps substance P research informative without reducing it to either a harmful-peptide label or a proposed treatment. The molecule, precursor scope, signalling compartment and outcome all belong in a careful reading note.
Sources and further detail
- PubChem — Substance P, CID 36511 (opens in a new tab)
Sequence, amidated terminus and preferred receptor description checked. No symptom-treatment claim adopted.
- NCBI Gene — Human TAC1 (opens in a new tab)
Reviewed precursor-product summary and transcript-variant information read. Gene-level evidence is not represented as a mature-peptide assay.
- Jensen and colleagues — Endosomal NK1 receptor signalling (opens in a new tab)
Original 2017 abstract and figure descriptions read. Rat spinal-neuron and mouse nociception models explicitly checked; mechanistic findings are not presented as a human treatment result.
Sources checked 19 September 2026. Worked examples are illustrative unless a supplied report is explicitly identified. This article has not undergone independent scientific peer review.